SCHEMBL1391979

SCHEMBL1391979

CCOc1nc(Cl)nc(Nc2ccc3[nH]c(=O)[nH]c3c2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.52
▸ MAPT P10636 5/20 0.51
▸ MEN1 O00255 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ LMNA P02545 1/20 0.51
▸ KDM4E B2RXH2 2/20 0.49
▸ NFKB1 P19838 1/20 0.49
▸ GAA P10253 1/20 0.48
▸ AURKA O14965 1/20 0.47
▸ AURKB Q96GD4 1/20 0.47
▸ PDE4B Q07343 1/20 0.45
▸ PDE4D Q08499 1/20 0.45
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ CA9 Q16790 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ BCL6 P41182 2/20 0.42
▸ BCOR Q6W2J9 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.41
▸ JAK1 P23458 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10282840 0.93 POLB (0.52) POLBMAPTMEN1KMT2ALMNA
SCHEMBL1392662 0.92 POLB (0.51) POLBMAPTMEN1KMT2ALMNA
SCHEMBL1392137 0.81 MAPT (0.47) POLBMAPTMEN1KMT2ALMNA
SCHEMBL1391379 0.78 MAPT (0.64) MAPTMEN1KMT2ALMNAKDM4E
SCHEMBL1391444 0.77 POLB (0.47) POLBMAPTMEN1KMT2ALMNA
SCHEMBL1391256 0.75 CCNE1 (0.43) CA1CA2CA9JAK3
SCHEMBL13950335 0.74 POLB (0.66) POLBMAPTMEN1KMT2ALMNA
SCHEMBL1391478 0.74 PDE4B (0.81) POLBMAPTMEN1KMT2ALMNA
SCHEMBL15501260 0.73 AURKA (0.51) POLBMAPTMEN1KMT2AKDM4E
SCHEMBL1391966 0.73 MAPT (0.50) POLBMAPTMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof PROGENICS PHARMACEUTICALS, INC. (US) 2012-01-12 — — US disclosed
EP-2231624-A2 TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF Progenics Pharmaceuticals, Inc. (US) 2010-09-29 — — EP disclosed
WO-2009091388-A2 TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF PROGENICS PHARMACEUTICALS, INC. (US) 2009-07-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof HAVCR2, ZC3HAV1, MAVS POLB 2680/4885MAPT 3654/4885MEN1 4840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback